Real-world Study on Comprehensive Treatment of Esophageal Cancer Based on Precision Radiotherapy

Esophageal Cancer Clinical Trial

Official title:

Real-world Study on Comprehensive Treatment of Esophageal Cancer Based on Precision Radiotherapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05543057
• Other study ID #: 22/036-3237
• Status: Recruiting
• Start date: January 1, 2020
• Est. completion date: January 1, 2026

Study information

• Verified date: September 2022
• Source: Chinese Academy of Medical Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Radiotherapy is one of the main treatments for locally advanced esophageal carcinoma (EC). The accuracy of the existing imaging methods in diagnosing and predicting therapeutic efficacy is disappointing, which increases the difficulty in clinical decision-making. In this study, based on a continuous cohort of EC treated with radiotherapy, the clinical and pathological factors of the patients are used to classify them into the appropriate therapeutic group. By multiple liquid biopsy technologies, combining with radiomics, we intend to construct prediction models of prognosis, therapeutic effect and toxicity. The aim of this RWS is to provide appropriate individualized regimen, further optimize the treatment mode based on precision radiotherapy and improve the outcome and quality of life of EC patients.

Description:

Radiotherapy is one of the main treatments for locally advanced esophageal squamous cell carcinoma (ESCC). The guidelines recommend neoadjuvant concurrent chemoradiotherapy plus surgery for resectable or potentially resectable patients; for unresectable patients, definitive chemoradiotherapy is the standard treatment. However, due to the complexity of the biological behavior of esophageal cancer (EC) and individual differences, fully complying with guideline recommendations in clinical practice is difficult and idealized. The results of prospective clinical trials are difficult to meet the demand of clinical diagnosis and treatment, thus, carrying out high-quality real-world study (RWS) is necessary.

Three-dimensional conformal radiotherapy (3DCRT) for unresectable EC yields 5-year OS rates of 34%-45.6%, which is an improvement over the rates reported in the RTOG 85-01 and 94-05 studies. Even so, there is still room for improvement of local control rate and overall survival. The accuracy of the existing imaging methods [computed tomography (CT), magnetic resonance imaging (MRI), endoscopic ultrasonography (EUS), endoscopic ultrasonography (EUS), as well as positron-emission tomography (PET)-CT, etc.] in diagnosing and predicting therapeutic efficacy is disappointing, which increases the difficulty in clinical decision-making. It is worthy to investigate an appropriate individualized radiation regimen based on different treatment sensitivity.

In this study, based on a continuous cohort of EC treated with radiotherapy, the clinical and pathological factors of the patients are used to classify them into the appropriate therapeutic group. Collect the blood and saliva samples before, during and after radiotherapy; the remaining diagnostic biopsy tissue samples. By using multiple liquid biopsy technologies [microbial flora, circulating tumor DNA (ctDNA), genome, RNA, and immunophenotype, ect.], combining with radiomics, construct prediction models of prognosis, therapeutic effect and toxicity. The aim of this RWS is to provide appropriate individualized regimen, further optimize the treatment mode based on precision radiotherapy and improve the outcome and quality of life of EC patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: January 1, 2026
• Est. primary completion date: January 1, 2026
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Pathology proved esophageal cancer

• ECOG PS =3

• Signed Informed consent

Exclusion Criteria:

• Pregnant and lactating women

• Others that researchers consider inappropriate

Related Conditions & MeSH terms

• Esophageal Cancer
• Esophageal Neoplasms

Intervention

Radiation:
• 3DCRT
Three-dimensional conformal radiotherapy (3DCRT)

Locations

Country	Name	City	State
China	Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Zefen Xiao

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Biomarkers to predict radiotherapy efficacy	potential biomarkers in tumor samples and blood samples	baseline/through study completion, an average of 2 year
Primary	1-, 2-, 3-year overall survival	Overall survival	From treatment initiation to death from any cause or censor, assessed up to 36 months
Secondary	1-, 2-, 3-year progression-free survival	Progression-free survival	From treatment initiation to first documented progression or death or censor, assessed up to 36 months
Secondary	Rate of acute toxicity (any and above grade 3)	Toxicities according to CTCAE criteria	From enrollment to 3 months after treatment
Secondary	Rate of acute/late toxicity (any and above grade 3)	Toxicities of chemoradiation therapy	After 3 months of enrollment
Secondary	1-month short-term efficacy	Short-term efficacy	Assessed 1-month after radiotherapy (short-term) according to RECIST 1.1
Secondary	Quality of Life change, QoL	measurement basing on EORTC (Quality of life of patients with oesophageal cancer) QLQ-C30 tables	1/3/6/12/24 months after radiotherapy
Secondary	Quality of life of patients with oesophageal cancer	measurement basing on EORTC (Quality of life of patients with oesophageal cancer) QLQ-OES18 tables	1/3/6/12/24 months after radiotherapy